Becton Dickinson Total Liabilities 2010-2022 | BDX

Becton Dickinson total liabilities from 2010 to 2022. Total liabilities can be defined as the total value of all possible claims against the corporation.
  • Becton Dickinson total liabilities for the quarter ending September 30, 2022 were $27.652B, a 8.4% decline year-over-year.
  • Becton Dickinson total liabilities for 2022 were $27.652B, a 8.4% decline from 2021.
  • Becton Dickinson total liabilities for 2021 were $30.189B, a 0.19% decline from 2020.
  • Becton Dickinson total liabilities for 2020 were $30.247B, a 1.42% decline from 2019.
Becton Dickinson Annual Total Liabilities
(Millions of US $)
2022 $27,652
2021 $30,189
2020 $30,247
2019 $30,684
2018 $32,910
2017 $24,786
2016 $17,953
2015 $19,314
2014 $7,394
2013 $7,106
2012 $7,225
2011 $5,602
2010 $4,216
2009 $4,162
Becton Dickinson Quarterly Total Liabilities
(Millions of US $)
2022-09-30 $27,652
2022-06-30 $27,706
2022-03-31 $30,261
2021-12-31 $29,203
2021-09-30 $30,189
2021-06-30 $30,199
2021-03-31 $30,094
2020-12-31 $30,085
2020-09-30 $30,247
2020-06-30 $29,937
2020-03-31 $32,565
2019-12-31 $30,750
2019-09-30 $30,684
2019-06-30 $30,736
2019-03-31 $31,289
2018-12-31 $31,528
2018-09-30 $32,910
2018-06-30 $32,620
2018-03-31 $33,421
2017-12-31 $34,116
2017-09-30 $24,786
2017-06-30 $24,579
2017-03-31 $16,158
2016-12-31 $16,735
2016-09-30 $17,953
2016-06-30 $17,983
2016-03-31 $18,570
2015-12-31 $18,823
2015-09-30 $19,314
2015-06-30 $19,826
2015-03-31 $21,134
2014-12-31 $13,435
2014-09-30 $7,394
2014-06-30 $6,996
2014-03-31 $6,935
2013-12-31 $6,957
2013-09-30 $7,106
2013-06-30 $6,871
2013-03-31 $7,041
2012-12-31 $7,160
2012-09-30 $7,225
2012-06-30 $6,790
2012-03-31 $6,719
2011-12-31 $6,686
2011-09-30 $5,602
2011-06-30 $5,322
2011-03-31 $5,245
2010-12-31 $5,193
2010-09-30 $4,216
2010-06-30 $3,878
2010-03-31 $3,794
2009-12-31 $3,834
2009-09-30 $4,162
2009-06-30 $3,637
2009-03-31 $2,772
Sector Industry Market Cap Revenue
Medical Medical & Dental Supplies $71.518B $18.870B
Becton, Dickinson and Company, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. BD's operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. The company's organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional. BD Medical: BD Medical's major product lines include needles, syringes and intravenous catheters for medication delivery and generic prefilled injectables. BD Life Sciences - BD Diagnostics provides products for the safe collection and transport of diagnostics specimens to detect a broad range of infectious diseases, healthcare-associated infections and cancer. BD Biosciences produces research and clinical tools that facilitate the study of cells to gain a better understanding of normal and disease processes. With the acquisition of C.R. Bard, BD added a new segment - BD Interventional.
Stock Name Country Market Cap PE Ratio
McKesson (MCK) United States $54.853B 16.21
AmerisourceBergen (ABC) United States $35.786B 15.79
Laboratory Of America Holdings (LH) United States $21.403B 10.73
Cardinal Health (CAH) United States $21.201B 16.27
West Pharmaceutical Services (WST) United States $18.090B 27.64
Cooper (COO) United States $15.905B 24.89
CONMED (CNMD) United States $2.752B 27.36
Invacare (IVC) United States $0.018B 0.00